basmifrelutide + liraglutide

LY3025876 + liraglutide is a combination therapy investigated by Eli Lilly and Company for the treatment of type 2 diabetes mellitus. The combination consists of basmifrelutide (LY3025876), a long-acting agonist of the glucose-dependent insulinotropic polypeptide (GIP) receptor, and liraglutide, a well-established glucagon-like peptide-1 (GLP-1) receptor agonist. Basmifrelutide is a peptide designed to mimic the activity of endogenous GIP, which enhances insulin secretion in a glucose-dependent manner. Liraglutide is a recombinant DNA-derived polypeptide that stimulates insulin release and inhibits glucagon secretion. By combining these two incretin mimetics, the therapy aims to achieve superior glycemic control and metabolic benefits compared to monotherapy. Clinical development reached Phase 1, where the safety, pharmacokinetics, and pharmacodynamics of the co-administered agents were evaluated in patients with T2DM.

Other names

LY3025876 + liraglutidebasmifrelutide + liraglutide